Epidemiologist Robert Haile has joined the faculty of the department of medicine, division of hematology-oncology at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai in Los Angeles. He will also be associate director for Translational Population Science. Most recently a professor in the Department of Medicine at Stanford University School of Medicine, Haile brings to... […]
American Society for Radiation Oncology will award its annual Survivor Circle grants to two San Diego-based cancer support charities: Cancer Angels of San Diego and The Seany Foundation. Cancer Angels of San Diego was founded in 2007 after founder and president Eve Beutler met a single mother with stage IV breast cancer who was having... […]
A new partnership between the American Cancer Society and the Melanoma Research Alliance will fund research aimed at decreasing side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefits. FDA has approved use of checkpoint drugs to combat seven cancer types including lung, head and neck, kidney cancer, bladder cancer, Merkel... […]
Michael Joiner, a professor in the division of radiation oncology, department of oncology, at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, will be honored by the European Society for Radiotherapy and Oncology with the 2018 ESTRO Lifetime Achievement Award. Joiner is the first American to receive the award since... […]
MD Anderson has simplified its power structure, eliminating the three executive vice president positions and flattening out the box diagram, with six vice presidents and senior vice presidents reporting directly to the president.
Under the House version of the agriculture funding bill for fiscal 2018, NIH would be allowed to transfer Cancer Moonshot money to FDA.
The NCI Board of Scientific Advisors and the National Cancer Advisory Board unanimously approved nine Cancer Moonshot-related funding opportunity announcements.
The Bidens are now official players in the realm of oncopolitics.
FDA granted regular approval to the combination of rituximab and hyaluronidase human (Rituxan Hycela) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
FDA granted regular approvals to dabrafenib and trametinib (Tafinlar and Mekinist) administered in combination for patients with metastatic non-small cell lung cancer with BRAF V600E mutation as detected by an FDA-approved test.
